Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinxiang Shugan is a Traditional Chinese Medicine (TCM) formulation developed by Shanghai Shuangji Pharmaceutical for the treatment of mild to moderate depression. It is specifically indicated for patients presenting with Liver Qi stagnation and Spleen deficiency syndrome, a common diagnostic pattern in TCM characterized by emotional distress, fatigue, and digestive issues. The formulation is designed to soothe the liver, regulate Qi, and strengthen the spleen. It has been evaluated in Phase IV clinical trials in China to assess its safety and efficacy in a broader patient population for the management of depressive symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinxiang Shugan.